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Non-CGDWe present a 70-year-old male patient of Greek origin with choreatic movements of the tongue and face, lower
limb muscle weakness, peripheral neuropathy, elevated creatinephosphokinase (CPK), acanthocytosis and
haemolysis in the absence of Kell RBC antigens with an additional Factor IX-deﬁciency. Genetic testing for muta-
tions in the three exons of the XK gene revealed a previously unreported hemizygous single base-pair frameshift
deletion at exon 1 (c.229delC, p.Leu80fs). In conclusion, we hereby describe a rare phenotype of a patient with
McLeod syndrome which was discovered coincidentally during routine blood group testing and consecutively
genetically conﬁrmed.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
McLeod syndrome is a rare X-linked multisystemic disease caused by
mutations in the XK gene, which is thought to encode for a membrane
transporter [1]. This rare syndrome together with autosomal recessive
chorea-acanthocytosis forms the core of the neuroacanthocytosis
syndromes, both featuring an estimated prevalence of less than 1–5/
1,000,000 [2]. With an onset of neurological symptoms mostly
around the 4th decade, the McLeod syndrome is a slowly progressive
multisystemic disease comprising acanthocytosis, haemolysis, chronic
anaemia, hepatosplenomegaly, cardiomyopathy, myopathy, neuropathy,
choreatic movement disorders, psychiatric manifestations and cognitive
decline as the most common symptoms, with additional occurrence of
more rare multi-system features being possible [3]. Not only the clinical
phenotype of McLeod syndrome but also the mutational spectrum of
the XK gene shows heterogeneity, with gross deletions, spanning theNeuroscience, UCL Institute of
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. Open access under CC BY license.entire or a signiﬁcant part of the XK coding region, as well as small
frameshift indels, and single nucleotide substitutions described as asso-
ciatedwith the phenotype. Their common ground is the prediction of an
absent or truncated, non-functional gene product [3]. We hereby pres-
ent a patient with a novel XK frameshift mutation associated with a
McLeod syndrome without signs of chronic granulomatous disease
(CGD).
2. Case report
A70-year-old Greekmanwas referred to theNeurologyDepartment
of the Papageorgiou Hospital in Thessaloniki. The main initial ﬁnding
was choreatiform tongue movements reported by the haematology
unit that detected a weak expression of K red blood cell antigens,
acanthocytosis, haemolysis, and a form of Factor IX deﬁciency when
screening his blood type prior to a blood transfusion needed for a sched-
uled surgical procedure. Those tongue movements were noted recently
andwere attributed by the family and the proband to his ill-ﬁtting den-
ture. The patient also had a slight generalised restlessnesswith frequent
changes of posture but without any tic-like or choreiform movements
of any particular part of his body apart from his tongue and the face.
Fig. 1. A) Family pedigree. The arrow indicates the proband. Black ﬁlled symbols indicate affected individuals, while half-ﬁlled indicate unaffected carriers of the mutation; B) Chromato-
grams depicting themutation segregating in this family; C) Protein alignment showing conserved positions across species and the very premature stop codon (markedwith the asterisk)
caused by the c.229delC frameshift mutation (WT — human wild-type allele; Mut — human mutant allele).
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tongue, and lower limb muscle weakness with muscle wasting.
His past medical history includes severe progressive skeletal defor-
mities after the age of 50, with osteoarthritis of the knees bilaterally
that resulted in severe varus deformities of the knees.
The patient had a brother who died at the age of 60, and presented
with severe facial dyskinesias, chorea and schizophrenia like psychosis.
His sister, who died at the age of 70 after an acute ischemic stroke, was
referred as being healthy until that incident. His 38-year-old daughter
andhis 35-year-old son are both healthy (Fig. 1A). There is no additional
family history regarding neuropsychiatric diseases.
3. Clinical investigations
Laboratory investigation revealed blood type group A1, DAT
negative (−), IAT positive (+). Antibody identiﬁcation panel testing
demonstrated panagglutination of the same intensity in all cellular
lines in the LISS/Coombs phase. Enzyme phase, 4 °C incubation phase
and auto control (A/C) were negative. His detailed blood group proﬁle
was: C (+), c (+), D (+), E (−), e (+), Cw (−), K (−), k (−),
Kpa (−), Kpb (−), P1 (+), Lea (−), Leb (+), Lua (−), Lub (+),
Jka (+), Jkb (+), M (+), N (+), S (+), s (+), Fya (−), and Fyb (+).Fig. 2. Acanthocytosis in peripheral blood. The smear shows freqPeripheral blood smear revealed the existence of acanthocytes (Fig. 2)
at a percentage of 19% of all red blood cells. Other abnormal laboratory
values included: Factor IX 8% (normal values 60−150%), Activated
Partial Thromboplastin Time (APTT) 58.1 (normal value 30.0 s), Partial
Thromboplastin Time Lupus Anticoagulans (PTT-LA) 61.3 (normal
value b45 s), Lactate dehydrogenase (LDH) 299 U/l (normal values
135–225), creatinephosphokinase 1400 U/l (normal range in males
24–195 U/l). His further routine blood tests were normal. Electrophysi-
ological examination showed diffuse chronic sensorimotor peripheral
neuropathy of axonal type. A brain MRI did not show any abnormal
ﬁndings apart from mild cortical atrophy (Fig. 3). Neuropsychological
investigation and EEGwere normal. The patient did not present any car-
diac complications and had a normal echocardiogram and 24-hour
monitoring.
4. Genetic analysis
Sequence analysis of the three exons of the XK gene detected a hemi-
zygous single base-pair frameshift deletion (Fig. 1B) at exon 1 (c.229delC,
p.Leu80fs), leading to a very premature stop codon (Fig. 1C). Exons 2 and
3 revealed no further mutations in this gene. Primers and conditions are
available upon request. The deletion is absent in the patient's healthy sonuent acanthocytes, representing ~19% of all red blood cells.
Fig. 3. Proband's T1- (left panel) and T2-weighted axial (right panel) MRI at time of presentation without major abnormalities.
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(Fig. 1A–B). To the best of our knowledge, this variant has not been
previously reported and is not present in public databases, such as
dbSNP and exome variant server.
5. Discussion
McLeod syndrome belongs to the rare neuroacanthocytosis syn-
dromes with approximately a few hundred cases worldwide [4]. The dis-
ease distribution lacks obvious clusters and McLeod syndrome has been
described across Northern and Southern America, Europe, Japan
and recently China [4,5]. It is heterogeneous in its clinical spectrum
even within families (e.g., [6,7]), and its mutational spectrum is also
wide. So far, gross deletions, including large parts of the XK gene or
even nearby genes, small frameshift indels as well as point mutations
have been described, all resulting in the absence or the truncation of a
functional gene product [3].
In our patient the neurological phenotype became obvious rather
late in life and his haematological abnormalities were revealed coinci-
dentally during routine blood group testing. Interestingly, our patient
exhibits a Factor IX-deﬁciency, which to the best of our knowledge
has not yet been reported as co-occurring with McLeod syndrome.
The diagnosis ofMcLeod syndrome is generally based on the haema-
tological ﬁndings of weak Kell antigens. Therefore, carriers of this
phenotype could be diagnosed mainly in blood banks [5]. However,
themajority of cases have been diagnosed by neurologists due to prom-
inent neurological manifestations. The wide phenotypic spectrum of
the disease and the insidious onset usually delays the diagnosis. Many
patients could have been diagnosed properly if there was a follow up
of all carriers of theMcLeod blood group phenotype that are discovered
coincidentally, as in the patient described here. The genetic testing in
our patient revealed a novel single base-pair frameshift deletion at exon1 of the XK gene, which would lead to a very premature stop codon.
Even if the protein is produced it would lack more than 330 amino
acids (normal size 444 amino acids). We hereby were able to expand
the mutational spectrum of XKmutations leading to McLeod syndrome.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
The authors are grateful to the UK Medical Research Council (MRC)
and the Wellcome Trust/MRC Joint Call in Neurodegeneration award
(WT089698). S.W. is supported by a PhD-studentship of the Brain
Research Trust.
References
[1] Ho M, Chelly J, Carter N, Danek A, Crocker P, Monaco AP. Isolation of the gene
for McLeod syndrome that encodes a novel membrane transport protein. Cell
1994;77(6):869–80.
[2] Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. Orphanet J Rare Dis
2011;6:68.
[3] Danek A, Rubio JP, Rampoldi L, Ho M, Dobson-Stone C, Tison F, et al. McLeod
neuroacanthocytosis: genotype and phenotype. Ann Neurol
2001;50(6):755–64.
[4] Man BL, Yuen YP, Yip SF, Ng SH. The ﬁrst case report of McLeod syndrome in a Chinese
patient. BMJ Case Rep 2013. http://dx.doi.org/10.1136/bcr-2013-200205.
[5] Jung HH, Danek A, Frey BM. McLeod syndrome: a neurohaematological disorder. Vox
Sang 2007;93(2):112–21.
[6] Walker RH, Jung HH, Tison F, Lee S, Danek A. Phenotypic variation among
brothers with the McLeod neuroacanthocytosis syndrome. Mov Disord
2007;22(2):244–8.
[7] Chakravarty A, Bhattacharya P, Banerjee D, Mukherjee S. Mcleod syndrome:
report of an Indian family with phenotypic heterogeneity. Ann Indian Acad Neurol
2011;14(1):53–5.
